Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL) Meeting Abstract
| Authors: | Collins, G.; Horwitz, S.; Hamadani, M.; Samaniego, F.; Spira, A.; Caimi, P.; Davies, A.; Menne, T.; Fields, P.; Cruz, H.; He, S.; Boni, J.; Feingold, J.; Wuerthner, J.; Radford, J. |
| Abstract Title: | Analysis of clinical determinants driving safety and efficacy of camidanlumab tesirine (ADCT‐301, Cami) in relapsed/refractory (R/R) classical Hodgkin lymphoma (CHL) |
| Meeting Title: | 15th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 37 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2019 Jun 18-22 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2019-06-01 |
| Start Page: | 95 |
| End Page: | 97 |
| Language: | English |
| ACCESSION: | 136932793 |
| DOI: | 10.1002/hon.61_2629 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| PUBMED: | 31187525 |
| DOI/URL: | |
| Notes: | Meeting Abstract: O55 -- Source: cin20 |
